Filtered By:
Specialty: Infectious Diseases
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 742 results found since Jan 2013.
Africa: U.S. Medical Research Accelerating Quest for HIV Cure
[State Department]Washington -A new year will begin at the National Institute of Allergy and Infectious Diseases (NIAID) with an intensified focus on finding a cure for HIV, the virus that causes AIDS.
Source: AllAfrica News: HIV-Aids and STDs - December 23, 2013 Category: Infectious Diseases Source Type: news
Africa: NIH Chief - 20 Years of Democracy - - Women's Interagency HIV Study
[State Department]This blog post by Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, was published December 20 on the AIDS.gov website managed by the U.S. Department of Health and Human Services. There are no republication restrictions for use by U.S. embassies.
Source: AllAfrica News: HIV-Aids and STDs - December 23, 2013 Category: Infectious Diseases Source Type: news
NIH-created toxin can kill HIV-infected cells that persist despite treatment
(NIH/National Institute of Allergy and Infectious Diseases) A team including University of North Carolina and NIH scientists has demonstrated in a mouse model that an HIV-specific poison can kill cells in which the virus is actively reproducing despite antiretroviral therapy. According to the researchers, such a targeted poison could complement antiretroviral therapy, which dramatically reduces the replication of HIV in infected cells but does not eliminate them.
Source: EurekAlert! - Infectious and Emerging Diseases - January 9, 2014 Category: Infectious Diseases Source Type: news
Study Demonstrates NIH-Created Toxin Can Kill HIV-Infected Cells That Persist Despite Treatment
“A team including University of North Carolina and NIH scientists has demonstrated in a mouse model that an HIV-specific poison can kill cells in which the virus is actively reproducing despite antiretroviral therapy. According to the researchers, such a targeted poison could complement antiretroviral therapy, which dramatically reduces the replication of HIV in infected cells but does not eliminate them. …
“The immunotoxin, known as 3B3-PE38, was created in 1998 in the laboratories of Edward A. Berger, Ph.D., of the National Institute of Allergy and Infectious Diseases, and Ira Pastan, Ph.D., of the Nat...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 17, 2014 Category: Infectious Diseases Source Type: news
Case Western Reserve wins $12.7 million for AIDS research and clinical trials
(Case Western Reserve University) AIDS researchers from Case Western Reserve University and University Hospitals Case Medical Center have received a seven-year funding award from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.This award includes $12.7 million for core research funding and the potential of an additional $9 million to support clinical trials of promising treatments.
Source: EurekAlert! - Infectious and Emerging Diseases - January 22, 2014 Category: Infectious Diseases Source Type: news
Researchers launch Phase 1 clinical trial of potential MRSA treatment
(NIH/National Institute of Allergy and Infectious Diseases) Scientists have begun the first human clinical trial of EDP-788, an investigational oral antibiotic intended to treat methicillin-resistant Staphylococcus aureus infections. The Phase 1 trial, which will enroll as many as 64 healthy men and women ages 18 to 45, will evaluate the investigational drug's safety as well as how it is broken down and processed in the body.
Source: EurekAlert! - Infectious and Emerging Diseases - January 24, 2014 Category: Infectious Diseases Source Type: news
Durable end to AIDS will require HIV vaccine development
(NIH/National Institute of Allergy and Infectious Diseases) Broader global access to lifesaving antiretroviral therapies and wider implementation of proven HIV prevention strategies could potentially control and perhaps end the HIV/AIDS pandemic. However, a safe and at least moderately effective HIV vaccine is needed to reach this goal more expeditiously and in a more sustainable way.
Source: EurekAlert! - Infectious and Emerging Diseases - February 5, 2014 Category: Infectious Diseases Source Type: news
Test for persistent Lyme infection using live ticks shown safe in clinical study
(NIH/National Institute of Allergy and Infectious Diseases) In a first-of-its-kind study for Lyme disease, researchers have used live, disease-free ticks to see if Lyme disease bacteria can be detected in people who continue to experience symptoms such as fatigue or arthritis after completing antibiotic therapy.
Source: EurekAlert! - Infectious and Emerging Diseases - February 12, 2014 Category: Infectious Diseases Source Type: news
Recent HIV/AIDS News from NIAID and NIH
February 25, 2014: NIH Expands Focus of Research Funding Opportunity Targeting HIV Reservoirs
“The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health, both part of the National Institutes of Health, recently expanded the scientific scope of an HIV-cure related funding announcement to allow for a broader range of studies and approaches.
“Specifically, the funding opportunity 'Targeting Persistent HIV Reservoirs,' which was originally issued February 17, 2012, has been significantly expanded to allow for 'proposed basic research into the cellular an...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - February 28, 2014 Category: Infectious Diseases Source Type: news
Recent HIV/AIDS News from NIAID
March 5, 2014: Genetic Modification of Cells Proves Generally Safe as HIV Treatment Strategy
“Scientists today report initial results from humans on the safety and tolerability of a novel strategy to curb HIV disease by removing key cells from HIV-infected individuals, genetically modifying the cells to resist HIV infection and returning them to those individuals. The basic and pre-clinical research on this strategy, which eventually might help people control the virus without drugs, was funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.”...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - March 14, 2014 Category: Infectious Diseases Source Type: news
HIV vaccine research must consider various immune responses
(NIH/National Institute of Allergy and Infectious Diseases) Future HIV vaccine research must consider both protective immune responses and those that might increase susceptibility to infection
Source: EurekAlert! - Infectious and Emerging Diseases - April 3, 2014 Category: Infectious Diseases Source Type: news
Genetic defect may confer resistance to certain viral infections
(NIH/National Institute of Allergy and Infectious Diseases) A National Institutes of Health study reports that a rare genetic disease, while depleting patients of infection-fighting antibodies, may actually protect them from certain severe or recurrent viral infections.
Source: EurekAlert! - Infectious and Emerging Diseases - April 9, 2014 Category: Infectious Diseases Source Type: news
National Institutes of Health awards Mount Sinai contract to further influenza research
(The Mount Sinai Hospital / Mount Sinai School of Medicine) The National Institute of Allergy and Infectious Diseases has awarded a team of researchers from the Icahn School of Medicine at Mount Sinai for the Center on Influenza Pathogenesis. This center is one of five centers participating in the Centers of Excellence for Influenza Research and Surveillance.
Source: EurekAlert! - Infectious and Emerging Diseases - April 10, 2014 Category: Infectious Diseases Source Type: news
Recent HIV/AIDS News from NIAID
April 3, 2014: Future HIV Vaccine Research Must Consider Both Protective Immune Responses and Those That Might Increase Susceptibility to Infection
“Last year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, held a scientific meeting to examine why certain investigational HIV vaccines may have increased susceptibility to HIV infection. In a new perspectives article appearing in the journal Science, HIV research leaders from NIAID (Anthony S. Fauci, M.D., and Carl W. Dieffenbach, Ph.D.) and its grantees at Emory University (Eric Hunter, Ph.D.) and the ...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 11, 2014 Category: Infectious Diseases Source Type: news
Study sheds light on how the immune system protects children from malaria
(NIH/National Institute of Allergy and Infectious Diseases) According to a study published today in PLOS Pathogens, children who live in regions of the world where malaria is common can mount an immune response to infection with malaria parasites that may enable them to avoid repeated bouts of high fever and illness and partially control the growth of malaria parasites in their bloodstream. The findings may help researchers develop future interventions that prevent or mitigate the disease caused by the malaria parasite.
Source: EurekAlert! - Infectious and Emerging Diseases - April 17, 2014 Category: Infectious Diseases Source Type: news
